# Abbott and Surmodics sign agreement for SurVeil drug-coated balloon

Abbott and Surmodics entered an agreement granting Abbott exclusive worldwide commercialization rights for Surmodics' SurVeil drug-coated balloon, with collaboration on development, clinical trials, and regulatory activities for U.S. and European approval.

- Type: Contract
- Announced: 2018-02-27
- Value: $25.0M
- Status: announced
- Products: SurVeil drug-coated balloon
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Abbott](https://endata.com/companies/4479.md) (customer)
- [Surmodics](https://endata.com/companies/30343.md) (supplier)

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/abbott-and-surmodics-announce-agreement-for-next-generation-drug-coated-balloon-300604649.html), 2018-02-27: "Abbott will have exclusive worldwide commercialization rights for Surmodics' SurVeil drug-coated balloon to treat the superficial femoral artery."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.